Ingrid Ricard
0000-0002-7102-0936
1 paper found
Refreshing results…
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
Missing publications? Search for publications with a matching author name.